TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06508541

Intervention type: PROCEDURE
Intervention: ICG Guided surgery
Description: In ICG guided surgery group,Approximately 0.3 ml of ICG dissolved in 2.5 mg/ml of sterile water was injected submucosally by the endoscopic doctors through colonoscopy at two points around the tumor.All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure

Intervention type: PROCEDURE
Intervention: conventional surgery
Description: All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose

Intervention type: PROCEDURE
Intervention: conventional surgery
Description: All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose
Study: NCT06094504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spectral Lighting
Description: Spectral room lighting containing violet and blue wavelengths of light capable of stimulating non-visual opsins including OPN5 and OPN3.
Study: NCT05790850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative physical exercise
Description: Virtual instructor-guided twice weekly cycling-based high-intensity aerobic exercise program for a total of 30 days. Participants will use a study provided recumbent exercise bike and wristband fitness tracker to exercise and log the number of days they exercise with an instructor and self-directed cycling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative mindfulness meditation practice
Description: Daily self-directed mindfulness practice involving a guided imagery meditation for a total of 30 days. Participants will use a study provided guided-imagery meditation audio file loaded to a study provided wristband fitness tracker. Participants will log the number of days they listen to the audio file or participate in self-directed solitary psychological support.
Study: NCT05510921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimalist music group
Description: Participants in this group will listen individually a live session of minimalist music piano piece, in a break room in the oncology sector, lasting between 10 and 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimalist music + birdsongs group
Description: Participants in this group will listen individually a live session of minimalist music piano piece with the superposition of bird song sounds, in a break room in the oncology sector, lasting between 10 and 15 minutes.
Study: NCT06402838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7269162
Description: Participants will receive daily doses (one of three dose levels) of RO7269162 for up to 72 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive daily doses of placebo for up to 72 weeks.
Study: NCT05782270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: dual antiplatelet therapy combined with warfarin

Intervention type: DRUG
Group type: OTHER
Intervention: DAPT
Description: Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT
Description: Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)

Intervention type: OTHER
Group type: OTHER
Intervention: CE+CABG
Description: Coronary endarterectomy combined with coronary artery bypass grafting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CE+CABG
Description: Coronary endarterectomy combined with coronary artery bypass grafting
Study: NCT05248451

Intervention type: OTHER
Intervention: Not an Interventional Study
Description: Not an Interventional Study

Intervention type: OTHER
Intervention: Not an Interventional Study
Description: Not an Interventional Study
Study: NCT04666571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOKA
Description: The device is a digitally planned (using individual CT scan measured anatomic data) personalised opening wedge high tibial osteotomy (HTO) procedure using a custom 3D printed surgical guide and plate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tomofix or ActivMotion
Description: The comparators, Tomofix and ActivMotion, are the most widely used devices for HTO procedures in the UK. Surgical procedures using the Tomofix and ActiveMotion are similar to TOKA, however, they are not patient specific and do not use custom-made plates.
Study: NCT05140122

Intervention type: DRUG
Intervention: Multiple
Description: We will collect information on all medications taken by the caregiver and the person they care for.

Intervention type: OTHER
Intervention: Multiple
Description: We will collect information on all forms of therapy or medical intervention taken by the caregiver and the person they care for.
Study: NCT05876182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vancomycin
Description: The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vancomycin
Description: The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The investigator will identify potential participants and confirm the diagnosis of PSC. Subjects will be screened within 10 weeks before randomization to determine the eligibility. Study participants will be consecutively randomized to oral vancomycin or placebo and investigational drug and placebo dispensed.
Study: NCT06554184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20013 + dexamethasone + palonosetron placebo
Description: HR20013 + dexamethasone + palonosetron placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron + dexamethasone + HR20013 placebo
Description: Palonosetron + dexamethasone + HR20013 placebo
Study: NCT05248152

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Paracetamol and Ibuprofen
Description: Patients will receive paracetamol 1g and ibuprofen 400 mg before surgical incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: Patients will receive pregabalin 150 mg in the hour before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a placebo capsule in the hour before surgery and two intravenous doses of saline before surgical incision.
Study: NCT04497259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleevaluation
Description: Patients will answer to a questionnaire filled through a chatbot link

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleevaluation
Description: Patients will answer to a questionnaire filled through a chatbot link

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: A teleconsultation (skype-like connection) at 6 and 9 months after surgery
Study: NCT04872452

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Any combination of the following six 3-6mm skin biopsies may be taken: palm, dorsum of hand, calf, other non-genital and non-face (this last one includes areas for use as negative controls which are not on the distal limbs). No more than 6 biopsies will be taken at one time.The biopsy size 3-6mm and method (punch, shave or wedge) will be done depending on the biologic assay destined for the biopsy. While 3mm will be sufficient for microarray analysis, 6mm will be required for any cell sorting preceding microarray analysis.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy
Description: Any combination of the following six 3-6mm skin biopsies may be taken: palm, dorsum of hand, calf, other non-genital and non-face (this last one includes areas for use as negative controls which are not on the distal limbs). No more than 6 biopsies will be taken at one time.The biopsy size 3-6mm and method (punch, shave or wedge) will be done depending on the biologic assay destined for the biopsy. While 3mm will be sufficient for microarray analysis, 6mm will be required for any cell sorting preceding microarray analysis.
Study: NCT06135727

Intervention type: DEVICE
Group type: OTHER
Intervention: Maestro2 OCT
Description: 3D Wide (12mmx9mm) OCT scan using the Maestro (Topcon, Japan)

Intervention type: DEVICE
Group type: OTHER
Intervention: Maestro2 OCT
Description: 3D Wide (12mmx9mm) OCT scan using the Maestro (Topcon, Japan)
Study: NCT06495242

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct pulp capping and partial pulpotomy
Description: Two types of vital pulp therapy procedures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct pulp capping and partial pulpotomy
Description: Two types of vital pulp therapy procedures
Study: NCT05686590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality Headset
Description: The simulation scenario will be a pediatric hypoglycemia-induced seizure case, which will be done through an AR simulation. AR (Augmented Reality) headset, which is a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario.
Study: NCT05978180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device : HO-1
Description: The injection will be performed at Day 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device : HS-3
Description: The three injections will be performed at Days 1, 8 and 15.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device : SINOVIAL® ONE
Description: The injection will be performed at Day 1.
Study: NCT06225986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LMH-4-DCP
Description: Reminiscence-based intervention for family caregiver-Persons with Dementia (PwD) dyads to record and reflect on meaningful memories to address family caregivers' pre-loss grief and enhance relationship quality.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LMH-4-DCP access without reminiscence activities
Description: Participants in the attention control condition will have access to a version of LMH-4-DCP excluding reminiscence-specific activities.
Study: NCT06107972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Launching! to Adulthood (¡Iniciando! la Adultez) program
Description: The program includes cognitive behavioral and acceptance and commitment therapy, with a focus on developing goals during the transition to adulthood through a values framework. After a combined (parents and young adults) 90-minute introductory group meeting in-person, parents and the transition-aged young adults with ASD attend 9 separate, 90-minute weekly group telehealth meetings. Additionally, young adults have weekly personal coaching meetings for 30-minutes to discuss progress toward goals and barriers encountered. Leaders teach transition-aged young adult's skills through various social activities, as well as other skills (e.g., emotion regulation, cognitive diffusion) to help overcome barriers towards their goals. The treatment targets three core factors (i.e., mental health conditions, social skills, and coping with and adapting to stress). Leaders teach parents new parenting skills, knowledge of ASD, and readiness to support their young adult's transition to independent life.
Study: NCT05827653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX210c
Description: 3 times a week, for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX210c
Description: 3 times a week, for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 times a week, for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 times a week, for 28 days
Study: NCT05655091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLU or CZO as continuous infusion
Description: Continuous infusion FLU or CZO coupled with real-time TDM and subsequent dose adjustment. A loading dose will be administered prior to the first continuous infusion. The loading dose (maximum of 2g as licensed according to the SmPC) and the dose of the continuous infusion will be calculated according to a pharmacokinetic model taking into account patient's characteristics (e.g. age, sex) and the measured drug concentration. The maximum daily dose of FLU and CZO will not exceed 12 grams per day according to the SmPC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard FLU or CZO intermittent bolus administration
Description: Standard FLU or CZO intermittent bolus administration according to the local guidelines adjusted to the renal function without TDM-guided dose adjustment.
Study: NCT05018767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT05151848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Injection
Description: Adalimumab Injection injected subcutaneously every other week for 78 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 MG
Description: Tofacitinib 5 MG BID taken orally for 78 weeks
Study: NCT04323826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: olive oil-water mixture
Description: 50% olive oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: olive oil-water emulsion
Description: 50% olive oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coconut oil-water mixture
Description: 50% coconut oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coconut oil-water emulsion
Description: 50% coconut oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
Study: NCT06159023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bronchial washing using a thin bronchoscope
Description: For intervention, we plan to perform bronchial washing using a thin bronchoscope instead of bronchoalveolar lavage with the conventional thick bronchoscope to diagnose pulmonary TB.
Study: NCT06494930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: F-IMT
Description: A core stabilization exercise protocol including functional respiratory muscle training will be applied to the F-IMT group. IMT will be provided with the red Powerbreath Plus MR exercise device. Initial training intensity will be set at 50% of the MIP value measured at the athlete's first evaluation. Every two weeks, the athlete will be re-evaluated the new MIP value will be measured, and the training intensity will be adjusted to 50% of the newly measured MIP value. After the nose clip is attached, the athlete will be asked to take the device's mouthpiece into his mouth, close his lips tightly, and take a deep, fast, and powerful breath, then exhale slowly and completely with minimal effort. While the athlete does breathing exercises with the device, he will also do core stabilization exercises. Athletes will be asked to train 30 minutes daily, five days a week, for six weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Stabilization Exercise
Description: Only the core stabilization exercise protocol will be applied to the control group. Athletes will be asked to train 30 minutes a day, five days a week, for six weeks.
Study: NCT05942430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous costal osteochondral transplantation
Description: Operating steps:~1. Arthroscopic examination of the size and location of the talar osteochondral lesion;~2. Make a transverse incision (approximately 4 cm long) at the osteochondral junction of the fifth or sixth rib, and harvest an osteochondral column from the rib;~3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;~4. Trim the autograft according to the size of the lesion;~5. Fill the peri-lesion cavity with cancellous bone, and finally embed the costal osteochondral autograft into the talar defect, ensuring that the cartilage surface of the transplant to be flush with the normal talar cartilage around it;~6. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous iliac osteoperiosteal transplantation
Description: Operating steps:~1. Arthroscopic examination of the size and location of the talar osteochondral lesion;~2. Make an incision along the anterior iliac crest. At the time of exposure, pay attention not to damage the periosteum. Obtain a cylindrical osteoperiosteal column by an appropriate-sized harvester tube.~3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;~4. Fill the peri-lesion cavity with cancellous bone, and finally embed the iliac osteoperiosteal autograft into the talar defect, ensuring that the periosteum surface of the transplant to be flush with the normal talar cartilage around it;~5. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer.
Study: NCT06022783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention
Description: Watching a relaxing video with using VR-G for 20 minutes
Study: NCT05794906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (BAY1841788, Nubeqa)
Description: Coated tablet, 300 mg / tablet, oral.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching darolutamide
Description: Coated tablet, oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADT
Description: Luteinizing hormone-releasing hormone \[LHRH\] agonist/antagonists

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ADT
Description: Luteinizing hormone-releasing hormone \[LHRH\] agonist/antagonists
Study: NCT05067426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: high-intensity interval training sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: high-intensity interval training sessions
Study: NCT05543278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: Patients randomized to the Amiodarone Arm will receive a 5-day course of amiodarone after surgery.
Study: NCT06033781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Nightmares in Children
Description: The Cognitive Behavioral Therapy for Nightmares in Children (CBT-NC) is a brief, five-session manualized therapy designed to treat children ages 6-17. The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
Study: NCT06252259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choose to Move
Description: As described under study arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choose to Move
Description: As described under study arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choose to Move
Description: As described under study arm description
Study: NCT02078635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portfolio Plus Diet
Description: Foods on the Portfolio Plus plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran bread and soups) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese) and additional sources of plant proteins from pulses (eg. lentils, chickpeas, beans, etc); and 22.5 g almonds or equivalent of other nuts/1000 kcal and increase MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH-like (high fibre) dietary advice
Description: Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce red meat consumption, choose low fat dairy foods and a control margarine
Study: NCT04528862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature slides
Description: participants will view a presentation of nature slides

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Urban slides
Description: participants will view a presentation of urban slides
Study: NCT05967117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iohexol (320mgI/mL) with 120kVp
Description: Patient undergoing CT scan with 120kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol (320mgI/mL) with 100kVp
Description: Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol (270mgI/mL) with 100kVp
Description: Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 270 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol (240mgI/mL) with 100kVp
Description: Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 240 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
Study: NCT05716750

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D
Description: 50,000 IU vit D treatment for 8 weeks
Study: NCT04497259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical consultation
Description: Patients in the consultation arm will benefit from a classical face to face consultation at 6 and 9 months after surgery.